Can a targeted drug trio tame a rare amyloid disease?

NCT ID NCT06629818

Ongoing Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining daratumumab, venetoclax, and dexamethasone can produce a deep and rapid response in people newly diagnosed with light-chain (AL) amyloidosis who carry a specific genetic marker called t(11;14). The study enrolls 36 participants and measures how well the treatment controls the disease at 3 months. The goal is to see if this oral-friendly regimen can become a new standard for this patient group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of daratumumab, venetoclax, and dexamethasone
What this could lead to: If successful, this could offer a highly effective, oral-based treatment option for a specific genetic subtype of AL amyloidosis.
What could go wrong: This is a small, early-phase trial (36 participants) without a control group, so results may not generalize. The combination carries risks of infection and bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIGHT CHAIN (AL) AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIGHT CHAIN (AL) AMYLOIDOSIS

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.